Astrazenica vaccine — Competitive Intelligence Brief

Astrazenica vaccine (Astrazenica vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Immunology / Infectious Disease.

phase 3 Viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic

Target snapshot

Astrazenica vaccine (Astrazenica vaccine) — Samia Hassan El-Shishtawy. The AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19) uses a replication-deficient chimpanzee adenovirus vector to deliver the SARS-CoV-2 spike protein gene, triggering immune responses against the virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Astrazenica vaccine TARGET	Astrazenica vaccine	Samia Hassan El-Shishtawy	phase 3	Viral vector vaccine	SARS-CoV-2 spike protein
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
COMIRNATY intramuscular injection	comirnaty-intramuscular-injection	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
COVID-19 vaccination	COVID-19 vaccination	University Medical Center Groningen	marketed	vaccine	SARS-CoV-2 spike protein
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

1. Janssen Vaccines & Prevention B.V. · 5 drugs in this class
2. University of Oxford · 3 drugs in this class
3. Crucell Holland BV · 3 drugs in this class
4. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
5. Bharat Biotech International Limited · 2 drugs in this class
6. Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
7. London School of Hygiene and Tropical Medicine · 1 drug in this class
8. Samia Hassan El-Shishtawy · 1 drug in this class
9. University Medicine Greifswald · 1 drug in this class
10. Aeras · 1 drug in this class